BLTE · NASDAQ · Biotechnology

Belite Bio (ADR) (BLTE)

Develops oral investigational therapies for retinal and metabolic diseases.

$163.00
Pre-market+1.55 (+0.96%)
At close$161.45(+3.03%)

Something off on this page? Send us feedback.

Next report
Nov 9, 2026
in 67 days
EPS estimate
−$0.80
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.45−$0.50−$0.65−$0.38−$0.34−$0.70−$0.54Pending
Estimate−$0.36−$0.47−$0.53−$0.56−$0.60−$0.73−$0.73−$0.80
Surprise−25.0%−6.4%−22.6%+32.1%+43.3%+4.1%+26.0%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate$16.7M
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.80
Aug 2026−$0.73−$0.54+26.0%
Aug 2026−$0.73−$0.70+4.1%
May 2026−$0.60−$0.34+43.3%
Mar 2026−$0.56−$0.38+32.1%

The latest year is open to everyone — the 23 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Sep 2022
Aug 2022
Apr 2022
Mar 2022
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 9, 2026−$0.80
Aug 13, 2026−$0.73−$0.54+26.0%−2.1%
Aug 12, 2026−$0.73−$0.70+4.1%−7.1%
May 20, 2026−$0.60−$0.34+43.3%+0.6%
Mar 2, 2026−$0.56−$0.38+32.1%$16.7M−5.5%

The latest year is open to everyone — the 23 quarters behind it read with an account.

Sign in
Nov 10, 2025
Aug 11, 2025
May 13, 2025
Mar 17, 2025
Nov 12, 2024
Aug 9, 2024
May 13, 2024
Mar 11, 2024
Nov 13, 2023
Aug 8, 2023
May 10, 2023
Mar 31, 2023
Sep 30, 2022
Aug 10, 2022
Apr 29, 2022
Mar 31, 2022
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020